Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapies

DOI Web Site Web Site 被引用文献2件
  • Shin Jie Yong
    Department of Biological Sciences School of Medical and Life Sciences Sunway University Selangor Malaysia
  • Shiliang Liu
    Centre for Surveillance and Applied Research Public Health Agency of Canada Ottawa ON Canada

説明

<jats:title>Summary</jats:title><jats:p>The effects of coronavirus disease 2019 (COVID‐19), a highly transmissible infectious respiratory disease that has initiated an ongoing pandemic since early 2020, do not always end in the acute phase. Depending on the study referred, about 10%–30% (or more) of COVID‐19 survivors may develop long‐COVID or post‐COVID‐19 syndrome (PCS), characterised by persistent symptoms (most commonly fatigue, dyspnoea, and cognitive impairments) lasting for 3 months or more after acute COVID‐19. While the pathophysiological mechanisms of PCS have been extensively described elsewhere, the subtypes of PCS have not. Owing to its highly multifaceted nature, this review proposes and characterises six subtypes of PCS based on the existing literature. The subtypes are non‐severe COVID‐19 multi‐organ sequelae (NSC‐MOS), pulmonary fibrosis sequelae (PFS), myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), post‐intensive care syndrome (PICS) and medical or clinical sequelae (MCS). Original studies supporting each of these subtypes are documented in this review, as well as their respective symptoms and potential interventions. Ultimately, the subtyping proposed herein aims to provide better clarity on the current understanding of PCS.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ